Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shailender Bhatia

Showing results (91-100 of 123) with videos related to

Pageof 13
Sort By:
Journal for Immunotherapy of Cancer|May 11, 2022
Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinomaGino Kim In, Aparna Nallagangula, Jacob Seung Choi, et al.
Journal for Immunotherapy of Cancer|May 17, 2020
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trialSandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 StudyMichael B Atkins, F Stephen Hodi, John A Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2015
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell CarcinomaSumanta Pal, Arun Azad, Shailender Bhatia, et al.
Journal for Immunotherapy of Cancer|August 11, 2025
Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockadeLisa Tachiki, Yasman Moshiri, Daniel S Hippe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib StudyFunda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.
Cancer|December 8, 2016
Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation studyKelly G Paulson, Christopher W Lewis, Mary W Redman, et al.
Cancer Immunology Research|August 14, 2014
Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinomaKelly G Paulson, Andrew Tegeder, Christoph Willmes, et al.
Journal for Immunotherapy of Cancer|July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancerAnn W Silk, Christopher A Barker, Shailender Bhatia, et al.
JAMA Dermatology|July 8, 2026
ctDNA or Merkel Virus Antibodies for Surveillance of Merkel Cell Carcinoma RecurrenceManisha Thakuria, Tomoko Akaike, Ann W Silk, et al.
Pageof 13

Showing results (91-100 of 123) with videos related to

Sort By:
Pageof 13
Journal for Immunotherapy of Cancer|May 11, 2022
Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinomaGino Kim In, Aparna Nallagangula, Jacob Seung Choi, et al.
Journal for Immunotherapy of Cancer|May 17, 2020
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trialSandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 StudyMichael B Atkins, F Stephen Hodi, John A Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2015
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell CarcinomaSumanta Pal, Arun Azad, Shailender Bhatia, et al.
Journal for Immunotherapy of Cancer|August 11, 2025
Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockadeLisa Tachiki, Yasman Moshiri, Daniel S Hippe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib StudyFunda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.
Cancer|December 8, 2016
Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation studyKelly G Paulson, Christopher W Lewis, Mary W Redman, et al.
Cancer Immunology Research|August 14, 2014
Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinomaKelly G Paulson, Andrew Tegeder, Christoph Willmes, et al.
Journal for Immunotherapy of Cancer|July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancerAnn W Silk, Christopher A Barker, Shailender Bhatia, et al.
JAMA Dermatology|July 8, 2026
ctDNA or Merkel Virus Antibodies for Surveillance of Merkel Cell Carcinoma RecurrenceManisha Thakuria, Tomoko Akaike, Ann W Silk, et al.
Pageof 13